Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly in classical hematology. Its lead product, PYRUKYND® (mitapivat), targets hemolytic anemias and is FDA-approved for PK deficiency. With a focus on expanding its portfolio, Agios is advancing treatments for thalassemia and sickle cell disease. The company aims to leverage its expertise in cellular metabolism to address significant unmet medical needs in these areas.
This description was generated via AI from an annual report. Updated about 1 year ago.